Rockwell Medical Technologies, Inc. Begins Dosing Patients For SFP Phase IIb Clinical Study
Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end- stage-renal-disease market (ESRD), announced that it has begun dosing patients in its Phase IIb Dose-Ranging Clinical Study for Soluble Ferric Pyrophosphate (SFP), the Company’s physiological iron maintenance therapy drug.
